Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study
Recruiting
Observational Study
Arterial Pulmonary Hypertension (PAH)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 48 (estimated)
- Sponsor
- Qianfoshan Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Consent and sign the informed consent form
* Non-low-risk PAH treatment-naive patients
Exclusion Criteria:
* Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
* Pulmonary veno-occlusive disease/pulmonary capillary he…
Contacts